Pfizer reports Inspra data in STEMI patients

Pfizer Inc. (NYSE:PFE) said once-daily Inspra eplerenone initiated within 24 hours of the onset of ST-segment elevation myocardial infarction (STEMI) symptoms met the primary composite endpoint vs. placebo in the Phase III REMINDER trial. The study enrolled 1,012 acute STEMI patients without concomitant heart failure. The endpoint comprised the incidence of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation, ejection fraction of 40% or less after one month or an elevation of BNP/ N-terminal pro-brain natriuretic peptide (NT-proBNP) levels after one month. After a mean follow-up of 10.5 months, the primary composite endpoint occurred in 18.3% of patients in the Inspra group vs. 29.6% of patients in the placebo group (p<0.0001). Data were presented at the American College of Cardiology meeting in San Francisco. ...